Eisai Co Ltd
TSE:4523
Eisai Co Ltd
Net Income
Eisai Co Ltd
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eisai Co Ltd
TSE:4523
|
Net Income
¥79.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
7%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income
¥208.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income
¥312.4B
|
CAGR 3-Years
46%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income
¥335.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income
-¥78B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eisai Co Ltd
Glance View
Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.
See Also
What is Eisai Co Ltd's Net Income?
Net Income
79.2B
JPY
Based on the financial report for Dec 31, 2024, Eisai Co Ltd's Net Income amounts to 79.2B JPY.
What is Eisai Co Ltd's Net Income growth rate?
Net Income CAGR 10Y
7%
Over the last year, the Net Income growth was 11%. The average annual Net Income growth rates for Eisai Co Ltd have been 5% over the past three years , -6% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet